NCT02712567No Longer Available不适用
A Continuation Study of TH-CR-406/SARC021 for the Remaining Subjects Enrolled in TH-CR-406/SARC021 in the US
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.
详细描述
The goal of this study is to provide continuation therapy with TH-302 to patients with soft tissue sarcomas who obtained response or stabilization of disease with prior treatment on TH-CR-406/SARC021 protocol. After written informed consent has been obtained and eligibility has been established, patients will receive the study drug as part of the continuation study. Patients will receive treatment on study as long as they have clinical benefit and do not experience unacceptable toxicity.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee.
- •Previously enrolled on the TH-CR-406/SARC021 protocol and benefiting from treatment.
- •Study investigator deems continued participation is appropriate based on overall health of the patient.
排除标准
- •Any of the criteria for study discontinuation are met.
- •Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
- •Unwillingness or inability to comply with the study protocol for any reason.
研究者
相似试验
No Longer Available
不适用
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor TherapyMetastatic Renal Cell CancerNCT00655252Novartis Pharmaceuticals
撤回
2 期
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)Alpha 1-Antitrypsin DeficiencyNCT05146882Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
终止
2 期
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021SARS-CoV-2NCT04728347Arcturus Therapeutics, Inc.65
Unknown
2 期
SHR-1701 in Patients With Recurrent/Metastatic ScchnSquamous Cell Carcinoma of Head and NeckNCT04650633Jiangsu HengRui Medicine Co., Ltd.130
终止
2 期
Atacicept in Multiple Sclerosis Extension Study, Phase IIRelapsing Multiple SclerosisNCT00853762EMD Serono74